Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Total Non-Current Liabilities of $7.7 billion for Q2 2026, up 17.62% year-over-year from $6.6 billion in Q2 2025, and up 5.72% quarter-over-quarter from $7.3 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $7.7 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 17.62% year-over-year to $7.7 billion; the TTM figure through Jun 2026 stood at $7.7 billion (up 17.62% YoY), while the FY2025 annual figure was $7.3 billion, up 6.56% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $7.7 billion, up from $7.3 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $7.7 billion in Q2 2026, with the low at $5.6 billion in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $6.5 billion (2024), against an average of $6.5 billion.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities advanced 27.92% in 2023, then retreated 8.91% in 2024.
- Regeneron Pharmaceuticals' Total Non-Current Liabilities stood at $5.9 billion in 2022, then grew by 5.76% to $6.3 billion in 2023, then advanced by 9.3% to $6.8 billion in 2024, then rose by 6.56% to $7.3 billion in 2025, then climbed by 6.24% to $7.7 billion in 2026.
- Business Quant data shows REGN's Total Non-Current Liabilities at $7.7 billion in Q2 2026, $7.3 billion in Q1 2026, and $7.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 378.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.74 Bn |
| Mar 31, 2026 | 7.32 Bn |
| Dec 31, 2025 | 7.28 Bn |
| Sep 30, 2025 | 7.35 Bn |
| Jun 30, 2025 | 6.58 Bn |
| Mar 31, 2025 | 6.48 Bn |
| Dec 31, 2024 | 6.83 Bn |
| Sep 30, 2024 | 6.57 Bn |
| Jun 30, 2024 | 6.42 Bn |
| Mar 31, 2024 | 6.47 Bn |
| Dec 31, 2023 | 6.25 Bn |
| Sep 30, 2023 | 7.22 Bn |
| Jun 30, 2023 | 5.92 Bn |
| Mar 31, 2023 | 5.89 Bn |
| Dec 31, 2022 | 5.91 Bn |
| Sep 30, 2022 | 5.64 Bn |
| Jun 30, 2022 | 5.79 Bn |
| Mar 31, 2022 | 5.74 Bn |
| Dec 31, 2021 | 5.99 Bn |
| Sep 30, 2021 | 5.75 Bn |